503A vs 503B Compounding Pharmacies: What GLP-1 Patients Need to Know

What 503A and 503B Actually Mean Under Federal Law

The Food, Drug, and Cosmetic Act created two separate compounding frameworks, and the differences between them affect every patient receiving a GLP-1 from a compounding pharmacy. Section 503A governs traditional pharmacy compounding. A licensed pharmacist at a state-regulated pharmacy receives a valid prescription for a specific, identified patient and prepares that formulation in response. The pharmacy does not need to register with the FDA, and the finished product is not subject to FDA's new drug approval requirements, provided the drug is not on the FDA's list of drugs withdrawn from the market for safety reasons and is not a copy of a commercially available product made for reasons other than a specific patient need [3].

Section 503B created a second tier: the outsourcing facility. These are companies that register voluntarily with the FDA, submit to federal inspections, comply with current good manufacturing practice standards, and may produce compounded drugs in large batches without patient-specific prescriptions [4]. Their products can be sold to healthcare providers who then dispense them, which is why many telehealth platforms used 503B suppliers to fulfill GLP-1 prescriptions at scale between 2022 and 2024 [5].

The practical gap between these two tiers matters. A 503B facility making injectable semaglutide must follow sterility testing, container closure, and labeling standards that are similar in rigor to those applied to pharmaceutical manufacturers [4]. A 503A pharmacy is not held to the same federal inspection cadence, though state boards of pharmacy conduct their own oversight. Neither tier guarantees a product identical to Wegovy or Zepbound, because compounded drugs are by definition not FDA-approved [6].

How the FDA Shortage List Controlled Legal Compounding Access

The shortage list is the legal on-ramp and off-ramp for compounded GLP-1 production. Under FDCA Section 503B(d)(2), outsourcing facilities may compound drugs that appear on the FDA's drug shortage list [4]. The same shortage status has historically been treated as supporting the "clinical difference" justification used by 503A pharmacies [3]. When the FDA declares a shortage over, that legal foundation shifts.

Semaglutide (the active ingredient in Wegovy and Ozempic) appeared on the FDA shortage list starting in 2022 as demand far outpaced Novo Nordisk's manufacturing capacity [7]. Tirzepatide (Mounjaro, Zepbound) entered shortage status in the same period [8]. Both shortages enabled a surge of compounded supply that, by some estimates, reached more than one million Americans at peak volume [9].

The FDA removed tirzepatide from the shortage list in October 2024 [8]. Semaglutide's shortage status ended in February 2025 [7]. At that point, 503B outsourcing facilities lost the legal basis to continue bulk-batch production of copies of these molecules. The FDA issued guidance stating that 503B facilities needed to wind down such production within a defined transition window [6]. 503A pharmacies retained more flexibility, because patient-specific compounding under 503A depends on individual clinical circumstances, not only shortage status [3].

SURMOUNT-1 (N=2,539) established that tirzepatide 15 mg produced a mean weight loss of 22.5% at 72 weeks versus 2.4% with placebo [2], data that drove the sustained demand behind the shortage. STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [10]. Those outcomes explain why patients and clinicians fought to preserve access through any available channel.

The Legal Status of Compounded Semaglutide and Tirzepatide in 2025

503B mass-compounding of semaglutide and tirzepatide copies is no longer legally supported after the shortage resolutions [6]. 503A patient-specific compounding remains legally permissible under federal law when a licensed prescriber determines that a commercially available product does not meet a specific patient's clinical needs. Acceptable justifications include documented hypersensitivity to an excipient in the branded product, a need for a dose strength that the manufacturer does not offer, or a prescriber-documented clinical reason why the approved drug is not appropriate for that patient [3].

Telehealth companies that were dispensing compounded semaglutide or tirzepatide to large general populations, without individualized clinical rationale, faced a direct compliance problem after the shortages ended [6]. The FDA's enforcement focus in 2025 shifted to pharmacies using unapproved salt forms such as semaglutide sodium or semaglutide acetate, which the agency stated are not the same active ingredient as semaglutide base and therefore cannot be compounded under the shortage provisions even when a shortage existed [11]. That distinction is not semantic: semaglutide sodium has not been studied in any clinical trial for safety or efficacy at compounded doses.

Patients receiving compounded GLP-1 therapy in 2025 should confirm three things. First, their prescription comes from a licensed prescriber who has documented a patient-specific clinical reason for the compounded formulation. Second, the pharmacy is either a state-licensed 503A pharmacy with verifiable accreditation or a 503B facility with active FDA registration. Third, the active ingredient listed is semaglutide or tirzepatide (base form), not a salt form [11].

Safety Comparison: Compounded vs Brand GLP-1 Medications

Brand-name Wegovy and Zepbound have been tested in randomized controlled trials enrolling tens of thousands of participants. Wegovy's safety profile across the STEP program included nausea in approximately 44% of patients, vomiting in 24%, and diarrhea in 30%, with serious adverse events balanced against placebo at 8 weeks through 68 weeks [10]. The SELECT trial (N=17,604) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo over a median 34.2 months in patients with pre-existing cardiovascular disease and obesity [1]. Those outcomes are tied to the specific manufacturer's formulation, device, excipient profile, and pharmacokinetics established in the FDA approval package [12].

Compounded semaglutide and tirzepatide have no trial data. Zero randomized controlled studies have evaluated compounded versions for efficacy or safety. The FDA has stated that compounded products have not been reviewed for safety, efficacy, or quality [6]. That does not mean compounded products from a well-run 503B facility are automatically dangerous, but it does mean the evidence base is categorically different from what backs an FDA-approved label [13].

The specific risks that have led to adverse event reports include dosing errors from multi-dose vials without fixed injection pens, contamination from facilities that do not meet sterility standards, and substitution of related but non-equivalent molecules [11]. The FDA published a safety communication in 2024 noting it had received hundreds of adverse event reports associated with compounded GLP-1 preparations, including hospitalizations [11]. A 503B-produced injectable compounded semaglutide from a registered, FDA-inspected facility with certificates of analysis represents a meaningfully different risk profile than a product from an unregistered online vendor, but neither has the post-market pharmacovigilance database that Wegovy or Zepbound carries [6].

STEP-5 (N=304) demonstrated that semaglutide 2.4 mg maintained 15.2% mean weight loss at 104 weeks with a sustained safety profile consistent with the 68-week STEP-1 results [14]. SURMOUNT-4 (N=783) showed that patients who discontinued tirzepatide regained two-thirds of their prior weight loss within 88 weeks, reinforcing that GLP-1 therapy is long-term, which makes the quality and consistency of the formulation a clinical concern over time [15].

How to Verify a Legitimate Compounding Pharmacy

Verification is a three-step process. Speed through it before filling any prescription.

Step 1: Check the FDA's 503B outsourcing facility database. The FDA maintains a public list of all registered outsourcing facilities at fda.gov [4]. If a company claims 503B status and does not appear on that list, it is not a legitimate 503B facility. This search takes under two minutes.

Step 2: Check state pharmacy board licensure. Every 503A compounding pharmacy must hold a current license in the state where it operates and, in most cases, in the patient's state as well. State boards maintain public license verification tools. A pharmacy that cannot be found in state license records is operating illegally [3].

Step 3: Request a certificate of analysis. A legitimate compounding pharmacy will provide, on request, a certificate of analysis (COA) from an independent third-party laboratory confirming active ingredient identity, potency, and sterility testing for injectable products [4]. A pharmacy that refuses to supply a COA or cannot name the testing laboratory warrants avoidance.

Red flags that should stop a patient from ordering include: no requirement for a prescription, claims that the product is "research grade" or "not for human use," pricing dramatically below market without explanation, no published physical address, and pressure tactics to order large quantities upfront [11].

The table below outlines a practical decision framework for clinicians evaluating a compounding pharmacy for GLP-1 prescriptions.

| Verification Criterion | 503A Pharmacy | 503B Outsourcing Facility | |---|---|---| | FDA registration required? | No | Yes, mandatory | | FDA inspections? | No (state board only) | Yes, routine federal CGMP inspections | | Patient-specific Rx required? | Yes, always | No (can dispense to providers in bulk) | | COA from independent lab? | Best practice; request it | Required under CGMP | | Salt form (e.g., semaglutide sodium)? | Not permitted | Not permitted | | Post-shortage bulk GLP-1 copies legal? | No (unless individual clinical justification) | No |

Dosing and Formulation Differences Between Compounded and Brand Products

Wegovy is supplied as a single-use auto-injector pen pre-filled at five dose strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg [12]. Zepbound is supplied as single-dose auto-injector pens at 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg [13]. These delivery systems were specifically designed to reduce dose errors and improve injection consistency, both of which were validated in the clinical trials.

Compounded injectable versions typically come in multi-dose vials requiring the patient to draw up each dose with a separate syringe. Multi-dose vial errors are a documented source of incorrect dosing in clinical practice. Patients who have transitioned from branded pens sometimes miscalculate volume-to-dose conversions, particularly during the titration phase where the dose changes every four weeks [11].

Some 503A pharmacies offer dose strengths that are not available in the branded products. A prescriber might choose a compounded formulation at 0.1 mg weekly for a patient who requires a slower titration due to severe nausea. That is a legitimate clinical rationale under 503A rules, and that kind of individualized adjustment is precisely the use case the 503A framework is designed to support [3].

STEP-3 (N=611) paired semaglutide 2.4 mg with intensive behavioral therapy and produced a mean weight loss of 16.0% at 68 weeks [16]. SURMOUNT-2 (N=938) showed tirzepatide 15 mg reduced body weight by 15.7% in patients with type 2 diabetes at 72 weeks [17]. These results reflect the brand formulation at exact doses validated through clinical development, which is the dose consistency argument for preferring the approved product when access and cost allow.

STEP-2 (N=1,210) showed semaglutide 2.4 mg produced a 9.6% reduction in body weight in adults with type 2 diabetes at 68 weeks [18]. For patients with both obesity and type 2 diabetes, the clinical decision between brand and compounded should weigh those documented outcomes alongside cost and availability.

What Patients Currently on Compounded GLP-1 Should Do

Patients who started on compounded semaglutide or tirzepatide before the shortage resolutions are not automatically in a dangerous or illegal position. Their clinical situation depends on whether their current pharmacy remains compliant, whether their prescriber has documented an individualized clinical rationale, and whether they are receiving the base form of the active ingredient rather than a salt form [3][6][11].

A practical checklist follows.

First, ask your prescriber why a compounded formulation was chosen for you specifically. If the answer is only "it was cheaper" or "it was more available," that rationale does not satisfy the post-shortage 503A standard. A documented excipient intolerance, required dose adjustment, or other individualized reason is needed [3].

Second, confirm your pharmacy's license status using the methods above. The FDA's database of registered outsourcing facilities is updated regularly [4].

Third, if transitioning to Wegovy is clinically appropriate and financially accessible, STEP-8 (N=338) showed semaglutide 2.4 mg produced significantly greater weight loss than liraglutide 3.0 mg at 68 weeks (mean difference 6.6 percentage points), which provides context for why the higher-dose GLP-1 class represents the current standard of care for obesity pharmacotherapy [19].

SURMOUNT-3 (N=579) showed that tirzepatide after a 12-week intensive lifestyle intervention produced an additional 18.4% mean weight loss over 72 weeks, demonstrating that the approved drug's performance holds even when added sequentially after behavioral therapy [20].

The AACE/ACE obesity clinical practice guidelines specify that pharmacotherapy for obesity should be continued long-term and that medication selection should be based on individual patient factors including comorbidities, tolerability, and access [21]. That guidance supports the view that a patient who is responding well to a compounded formulation from a verified, compliant pharmacy, under a legitimate 503A prescription, is not acting against clinical guidelines.